Concentra Group Holdings Parent, Inc. (CON) Hit a 52 Week High, Can the Run Continue?
Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CON - Concentra Group Holdings Parent, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$38.60
DETAILS
HIGH:
$42.00
LOW:
$30.00
MEDIAN:
$40.00
CONSENSUS:
$38.60
UPSIDE:
6.04%
Stock News
Concentra Group Holdings Parent (NYSE:CON) Reaches New 52-Week High – Here’s Why
Concentra Group Holdings Parent, Inc. (NYSE: CON - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $36.83 and last traded at $36.37, with a volume of 37068 shares trading hands. The stock had previously closed at $36.21. Analyst Upgrades and Downgrades CON has been
Why Concentra's Quiet Healthcare Business Keeps Winning
The company is growing, widening its margins, paying down debt, and paying a dividend all at the same time. Wall Street sees more upside ahead and has tagged the stock with a full Buy rating.
CON EDISON LEADERSHIP TO WEBCAST INVESTOR RELATIONS PRESENTATION ON OCTOBER 6
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Consolidated Edison, Inc. (NYSE: ED) will webcast the company's Annual Investor Relations Update from 8:30 a.m.
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
CON EDISON TO WEBCAST INVESTOR PRESENTATION ON OCTOBER 6, 2026
NEW YORK , Sept. 16, 2026 /PRNewswire/ -- Consolidated Edison, Inc. (NYSE: ED) will webcast an investor presentation from 8:30 a.m.
Concentra Group Holdings Parent: Potential Beneficiary Of Increased Injuries From Data Center Capex
Concentra Group Holdings Parent, rated BUY, has surged 78% YTD, driven by market share gains and strong operating leverage. CON beat 2Q26 earnings estimates, with revenue up 10% YoY and adjusted EBITDA up 22.5%, aided by higher patient revenue per visit. Future growth may be propelled by additional state-level workers' compensation reimbursement increases and a robust M&A pipeline.
Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?
Concentra (CON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Concentra Expands Florida Footprint with New Daytona Beach Medical Center
DAYTONA BEACH, Fla.--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational medicine and workforce health services, today announced the opening of its newest Florida medical center and first location in Volusia County. The Daytona Beach medical center expands access to occupational health services for employers and employees throughout the Greater Daytona region. Daytona Beach sits at the intersection of two critical Florida transportation corridors and is emerging as a ce.
CON vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Are You Looking for a Top Momentum Pick? Why Concentra Group (CON) is a Great Choice
Does Concentra Group (CON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Concentra Appoints Tanner Newton Chief Financial Officer
DALLAS--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational medicine and workforce health services, today announced that Tanner Newton, senior vice president of strategy and finance, has been appointed executive vice president and chief financial officer, effective Nov. 1, 2026. Newton will continue to report to Matt DiCanio, Concentra's president and chief financial officer, who will become president and chief executive officer on Nov. 1, 2026. Newton will lead Concent.
3 Stocks to Add to Your Portfolio After Recent Broker Rating Upgrades
Concentra Group, QuinStreet and Arrow Electronics pair broker rating upgrades with strong projected earnings growth, making them stocks to consider.
Contrasting Concentra Group Holdings Parent (NYSE:CON) and Amarantus Bioscience (OTCMKTS:AMBS)
Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) and Concentra Group Holdings Parent (NYSE: CON - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Concentra Group (CON) is a Great Momentum Stock: Should You Buy?
Does Concentra Group (CON) have what it takes to be a top stock pick for momentum investors? Let's find out.
Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health
Concentra (NYSE: CON), the nation's leader in occupational medicine, today announced that nationally recognized occupational medicine leader Jill Rosenthal, M
Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health
DALLAS--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational medicine, today announced that nationally recognized occupational medicine leader Jill Rosenthal, MD, MPH, will join the company Sept. 1 and assume the role of chief medical officer, effective Jan. 1, 2027. Returning to the organization where she previously served in physician leadership roles, including area medical director, Dr. Rosenthal will lead Concentra's national clinical strategy, physician leadership,.
Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition
Concentra (NYSE: CON), the nation's leader in occupational and workforce health services, today announced completion of its acquisition of four Minnesota Occu
Concentra Strengthens Workforce Health Access in Minnesota Through Acquisition
DALLAS & MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational and workforce health services, today announced completion of its acquisition of four Minnesota Occupational Health (MOH) medical centers in the Twin Cities. The acquisition strengthens access to specialized occupational health care for Minnesota employees and connects experienced local care teams with Concentra's national clinical and operational resources. Beginning August 17, t.
Price Targets
Concentra price target raised to $40 from $28 at Wells Fargo
$40.00
(was $34.10)
Wells Fargo
Concentra price target raised to $42 from $37 at Truist
$42.00
(was $33.58)
David MacDonald
·
Truist Financial
Concentra price target raised to $41 from $32 at Deutsche Bank
$41.00
(was $34.21)
Deutsche Bank
Concentra price target raised to $40 from $35 at Mizuho
$40.00
(was $34.06)
Ann Hynes
·
Mizuho Securities
Concentra price target raised to $37 from $31 at Truist
$37.00
(was $31.39)
Truist Financial
Concentra initiated with a Buy at Goldman Sachs
$30.00
(was $24.92)
Scott Fidel
·
Goldman Sachs
Concentra price target raised to $32 from $29 at Deutsche Bank
$32.00
(was $24.67)
Deutsche Bank
Concentra price target raised to $31 from $30 at RBC Capital
$31.00
(was $22.14)
RBC Capital
Concentra price target raised to $52 from $38 at UBS
$52.00
(was $20.28)
UBS
Concentra price target raised to $26 from $24 at Goldman Sachs
$26.00
(was $22.74)
Goldman Sachs
Concentra's High-Quality Business Model Attracts Analyst Attention, Initiates With Buy Rating
$29.00
(was $23.36)
Justin Bowers
·
Deutsche Bank
Concentra initiated with a Buy at BofA
$30.50
(was $23.28)
Joanna Gajuk
·
Bank of America Securities
Concentra initiated with a Buy at Truist
$29.00
(was $23.41)
David MacDonald
·
Truist Financial